Home . Immediapress . Pr Newswire . Janssen Collaborates With ViiV Healthcare to Develop Two-Drug Single Tablet Regimen for the Maintenance Treatment of People Living With HIV

Janssen Collaborates With ViiV Healthcare to Develop Two-Drug Single Tablet Regimen for the Maintenance Treatment of People Living With HIV

PR NEWSWIRE

CORK, Ireland, June 12, 2014 /PRNewswire/ --

Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT®) and ViiV's Integrase Inhibitor dolutegravir(marketed as TIVICAY®) as the sole active ingredients for the maintenance treatment of people living with Human Immunodeficiency Virus (HIV).  The companies will further investigate development of this drug combination for pediatric use.

If successfully developed and approved by regulatory authorities, this treatment could offer people living with HIV who are virologically suppressed an option to switch from a standard three-drug therapy to a two-drug, Nucleoside Reverse Transcriptase Inhibitor (NRTI)-sparing antiviral regimen.  

"HIV remains a significant medical challenge, and our goal is to find new treatment regimens for patients," says Paul Stoffels, Chief Scientific Officer, Johnson & Johnson and Worldwide Chairman, Janssen. "We are pleased to collaborate with ViiV Healthcare in pursuing this shift in the HIV treatment paradigm and reaffirm our commitment to collaborate and develop new HIV treatments and fixed-dose regimens." 

Formulation and clinical development for the single tablet regimen will begin in the coming months.

Since the beginning of the HIV epidemic, almost 75 million people have been infected with the HIV virus.[1] It is estimated that 35 million people are currently living with HIV globally, with 2.5 million people becoming newly infected each year.[1],[2],[3]

Standard HIV-drug therapy contains three active components: a backbone of two NRTIs, plus either a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), Protease Inhibitor (PI) or Integrase Inhibitor (INI).

About EDURANT®  

EDURANT® (rilpivirine) is a prescription HIV medicine that is used with other antiretroviral medicines to treat Human Immunodeficiency Virus-1 (HIV-1)in adults:

EDURANT® does not cure HIV infection or AIDS. You should remain on your HIV medications without stopping to ensure that you control your HIV infection and decrease the risk of HIV-related illnesses. Ask your healthcare professional about how to prevent passing HIV to other people. 

Please read Important Safety Information below, and talk to your healthcare professional to learn if EDURANT® is right for you. 

Important Safety Information 

Can EDURANT® be taken with other medicines? 

EDURANT® may affect the way other medicines work and other medicines may affect how EDURANT® works and may cause serious side effects. If you take certain medicines with EDURANT®, the amount of EDURANT® in your body may be too low and it may not work to help control your HIV infection, and the HIV virus in your body may become resistant to EDURANT® or other HIV medicines that are like it. To help get the right amount of medicine in your body, you should always take EDURANT® with a meal. A protein drink alone does not replace a meal.

Do not take EDURANT® if:  

Your HIV infection has been previously treated with HIV medicines

You are taking any of the following medicines:

Especially tell your doctor if you take:  

This is not a complete list of medicines. Before starting EDURANT®,be sure to tell your healthcare professional about all the medicines you are taking or plan to take, including prescription and nonprescription medicines, vitamins, and herbal supplements. 

Before taking EDURANT®, also tell your healthcare professional if you have had or currently have liver problems (including hepatitis B or C), have ever had a mental health problem, are pregnant or planning to become pregnant, or breastfeeding. It is not known if EDURANT® will harm your unborn baby.

You and your healthcare professional will need to decide if taking EDURANT®is right for you.

What are the possible side effects of EDURANT®? 

EDURANT® can cause serious side effects including:  

Your immune system may get stronger and begin to fight infections. Tell your healthcare professional right away if you start having any new symptoms of infection.

Other common side effects of EDURANT® include depression, headache, trouble sleeping (insomnia), and rash.

This is not a complete list of all side effects. If you experience these or other symptoms, contact your healthcare professional right away. Do not stop taking EDURANT® or any other medications without first talking to your healthcare professional.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Product Information for more details:

http://www.edurant.com/sites/default/files/EDURANT-PI.pdf

About EDURANT® (rilpivirine)   

Rilpivirine was developed by Janssen R&D Ireland Ltd, one of the Janssen Pharmaceutical Companies.

The registered formulation of rilpivirine is a 25 mg film-coated tablet taken orally once daily.  Marketed as EDURANT®, rilpivirine is indicated, in combination with other ARVs, for the treatment of HIV-1 in ARV treatment-naïve adult patients. In most countries, including US and EU, this indication is further restricted to patients with a viral load < 100,000 copies/ mL.

Rilpivirine is available in the United States (US) and the European Union as part of a once daily fixed dose antiretroviral combination with Gilead Sciences Inc's tenofovir and emtricitabine. This combination, known as COMPLERA® (US) or EVIPLERA®, was granted marketing authorisation from the Food and Drug Administration in August 2011, with Gilead Sciences Inc being the marketing authorisation holder in the US, and from the European Commission in November 2011, with Gilead Sciences International Ltd. being the marketing authorisation holder in Europe, Middle East and Africa.

About TIVICAY® (dolutegravir)  

TIVICAY® (dolutegravir) is an integrase inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 in adults and children aged 12 years and older weighing at least 40 kg. Integrase inhibitors block HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells (T-cells). This step is essential in the HIV replication cycle and is also responsible for establishing chronic infection. It is available as a small, yellow, 50 mg tablet. Importantly, it can be taken with or without food and at any time of the day.

About Janssen    

At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in infectious diseases and vaccines, oncology, immunology, neuroscience, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world.  

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen R&D Ireland Ltd, any of the Janssen Pharmaceutical Companies and/or Johnson & Johnson.    

Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; general industry conditions including trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies.    

A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2013, including in Exhibit 99 thereto, and our subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at http://www.sec.govhttp://www.jnj.com or on request from Johnson & Johnson.  None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statements as a result of new information or future events or developments.)

1.   World Health Organization. Global summary of the AIDS epidemic. Available at: http://www.who.int/gho/hiv/en/. Last accessed June 2014.

2.   Hui Dy. Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res 2003; http://www.ncbi.nlm.nih.gov/pubmed/12547652 42(2):81-92.

3.   World Health Organization. Global summary of the AIDS epidemic. Available at: http://www.who.int/hiv/data/2012_epi_core_en.png. Last accessed June 2014.

MEDIA CONTACT:Ronan Collins +47-488-42500rcollin5@its.jnj.comINVESTOR RELATIONS:Stan Panasewicz +1-732-524-2524

Louise Mehrotra +1-732-524-6491

RIPRODUZIONE RISERVATA © Copyright Adnkronos.